Nutex Health restates FY2024 and Q1 2025; receives Nasdaq delisting notice for late filing

Nutex Health Inc.

Restatement due to misclassification of obligations for under-construction hospitals; liabilities increase $10-20M (Dec 2024) and $20-50M (Mar 2025); equity decreases correspondingly.
Material weakness in internal controls identified; company engaging accounting firm for remediation.
Nasdaq notice for late filing of Q2 2025 10-Q; 60 days to file or submit compliance plan.
Short seller report on July 22, 2025 caused stock drop of 16.5%; company disputes allegations.

item 2.02item 3.01item 4.02item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.